SCHEMBL6920840

SCHEMBL6920840

CC1(C)CCn2c1nc1cc(-c3ccccn3)ccc1c2=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.40
TGFBR1 P36897 1/20 0.38
METAP2 P50579 1/20 0.38
PIK3CD O00329 5/20 0.36
PIK3CA P42336 5/20 0.36
PIK3CG P48736 5/20 0.36
PIK3CB P42338 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
GSK3B P49841 1/20 0.36
DYRK1A Q13627 1/20 0.36
CTSD P07339 1/20 0.36
BACE1 P56817 1/20 0.36
DHODH Q02127 1/20 0.36
PRMT5 O14744 2/20 0.35
WDR77 Q9BQA1 1/20 0.35
NSD2 O96028 1/20 0.35
CNR2 P34972 1/20 0.35
RET P07949 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12059030 0.83 NPC1 (0.42) CYP3A4TGFBR1METAP2PIK3CDPIK3CA
SCHEMBL6922846 0.82 RAB9A (0.45) CYP3A4TGFBR1PIK3CDPIK3CAPIK3CG
SCHEMBL6921104 0.81 RAB9A (0.46) CYP3A4NPC1RAB9ATDP1NSD2
SCHEMBL6920819 0.80 RAB9A (0.43) CYP3A4TGFBR1NPC1RAB9ATDP1
SCHEMBL12059073 0.80 NPC1 (0.40) CYP3A4TGFBR1METAP2PIK3CDPIK3CA
SCHEMBL6923093 0.80 RAB9A (0.45) CYP3A4TGFBR1METAP2PIK3CDPIK3CA
SCHEMBL9994440 0.80 POLB (0.47) NPC1RAB9ATDP1
SCHEMBL6921660 0.79 CYP3A4 (0.38) CYP3A4TGFBR1METAP2PIK3CDPIK3CA
SCHEMBL6922494 0.79 NPC1 (0.42) CYP3A4TGFBR1NPC1RAB9ATDP1
SCHEMBL6922413 0.78 NPC1 (0.43) CYP3A4TGFBR1METAP2PIK3CDPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof SUNOVION PHARMACEUTICALS INC. (US) 2011-12-29 US disclosed
WO-2011075699-A2 COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. (US) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319380-A1 Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof GRM5, GRM2, GRM1 CYP3A4 4447/4885TGFBR1 3543/4885METAP2 2203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.